Suzhou Fushilai Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Suzhou Fushilai Pharmaceutical's earnings have been declining at an average annual rate of -10.1%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 31.1% per year. Suzhou Fushilai Pharmaceutical's return on equity is 0.8%, and it has net margins of 3.8%.
Key information
-10.1%
Earnings growth rate
-18.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -31.1% |
| Return on equity | 0.8% |
| Net Margin | 3.8% |
| Next Earnings Update | 23 Oct 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Suzhou Fushilai Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 409 | 15 | 50 | 45 |
| 31 Mar 24 | 429 | 66 | 49 | 43 |
| 31 Dec 23 | 489 | 112 | 50 | 41 |
| 30 Sep 23 | 559 | 157 | 50 | 41 |
| 30 Jun 23 | 593 | 184 | 49 | 40 |
| 31 Mar 23 | 583 | 189 | 47 | 42 |
| 01 Jan 23 | 568 | 177 | 48 | 41 |
| 30 Sep 22 | 567 | 161 | 45 | 39 |
| 30 Jun 22 | 537 | 147 | 44 | 35 |
| 31 Mar 22 | 548 | 133 | 42 | 30 |
| 01 Jan 22 | 522 | 120 | 38 | 29 |
| 31 Dec 20 | 477 | 141 | 35 | 23 |
| 31 Dec 19 | 452 | 146 | 39 | 18 |
| 31 Dec 18 | 375 | 93 | 32 | 21 |
| 30 Jun 18 | 378 | 78 | 47 | -2 |
| 31 Mar 18 | 376 | 77 | 47 | -1 |
| 31 Dec 17 | 375 | 77 | 47 | 0 |
| 30 Sep 17 | 362 | 69 | 55 | 4 |
| 30 Jun 17 | 348 | 61 | 62 | 8 |
| 31 Mar 17 | 335 | 60 | 65 | 4 |
| 31 Dec 16 | 322 | 59 | 68 | 0 |
| 30 Sep 16 | 308 | 63 | 54 | 0 |
| 30 Jun 16 | 294 | 68 | 40 | 0 |
| 31 Mar 16 | 277 | 61 | 40 | 0 |
| 31 Dec 15 | 245 | 48 | 36 | 0 |
| 31 Dec 14 | 144 | 6 | 25 | 0 |
| 31 Dec 13 | 167 | 39 | 27 | 0 |
Quality Earnings: 301258 has a large one-off loss of CN¥11.6M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: 301258's current net profit margins (3.8%) are lower than last year (31%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301258's earnings have declined by 10.1% per year over the past 5 years.
Accelerating Growth: 301258's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301258 had negative earnings growth (-91.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.6%).
Return on Equity
High ROE: 301258's Return on Equity (0.8%) is considered low.